460 related articles for article (PubMed ID: 28559247)
1. Mortality Associated with Bacteremia Due to Colistin-Resistant Klebsiella pneumoniae with High-Level Meropenem Resistance: Importance of Combination Therapy without Colistin and Carbapenems.
Machuca I; Gutiérrez-Gutiérrez B; Gracia-Ahufinger I; Rivera Espinar F; Cano Á; Guzmán-Puche J; Pérez-Nadales E; Natera C; Rodríguez M; León R; Castón JJ; Rodríguez-López F; Rodríguez-Baño J; Torre-Cisneros J
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559247
[TBL] [Abstract][Full Text] [Related]
2. Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection.
Giannella M; Trecarichi EM; Giacobbe DR; De Rosa FG; Bassetti M; Bartoloni A; Bartoletti M; Losito AR; Del Bono V; Corcione S; Tedeschi S; Raffaelli F; Saffioti C; Spanu T; Rossolini GM; Marchese A; Ambretti S; Cauda R; Viscoli C; Lewis RE; Viale P; Tumbarello M;
Int J Antimicrob Agents; 2018 Feb; 51(2):244-248. PubMed ID: 28842283
[TBL] [Abstract][Full Text] [Related]
3. Comparison of synergism between colistin, fosfomycin and tigecycline against extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolates or with carbapenem resistance.
Ku YH; Chen CC; Lee MF; Chuang YC; Tang HJ; Yu WL
J Microbiol Immunol Infect; 2017 Dec; 50(6):931-939. PubMed ID: 28716360
[TBL] [Abstract][Full Text] [Related]
4. Meropenem for treating KPC-producing Klebsiella pneumoniae bloodstream infections: Should we get to the PK/PD root of the paradox?
Del Bono V; Giacobbe DR; Marchese A; Parisini A; Fucile C; Coppo E; Marini V; Arena A; Molin A; Martelli A; Gratarola A; Viscoli C; Pelosi P; Mattioli F
Virulence; 2017 Jan; 8(1):66-73. PubMed ID: 27430122
[TBL] [Abstract][Full Text] [Related]
5. Predictors of outcome in ICU patients with septic shock caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae.
Falcone M; Russo A; Iacovelli A; Restuccia G; Ceccarelli G; Giordano A; Farcomeni A; Morelli A; Venditti M
Clin Microbiol Infect; 2016 May; 22(5):444-50. PubMed ID: 26850826
[TBL] [Abstract][Full Text] [Related]
6. Combination Regimens for Treatment of Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections.
Gomez-Simmonds A; Nelson B; Eiras DP; Loo A; Jenkins SG; Whittier S; Calfee DP; Satlin MJ; Kubin CJ; Furuya EY
Antimicrob Agents Chemother; 2016 Jun; 60(6):3601-7. PubMed ID: 27044555
[TBL] [Abstract][Full Text] [Related]
7. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study.
Tumbarello M; Trecarichi EM; De Rosa FG; Giannella M; Giacobbe DR; Bassetti M; Losito AR; Bartoletti M; Del Bono V; Corcione S; Maiuro G; Tedeschi S; Celani L; Cardellino CS; Spanu T; Marchese A; Ambretti S; Cauda R; Viscoli C; Viale P;
J Antimicrob Chemother; 2015 Jul; 70(7):2133-43. PubMed ID: 25900159
[TBL] [Abstract][Full Text] [Related]
8. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens.
Qureshi ZA; Paterson DL; Potoski BA; Kilayko MC; Sandovsky G; Sordillo E; Polsky B; Adams-Haduch JM; Doi Y
Antimicrob Agents Chemother; 2012 Apr; 56(4):2108-13. PubMed ID: 22252816
[TBL] [Abstract][Full Text] [Related]
9. Gentamicin therapy for sepsis due to carbapenem-resistant and colistin-resistant Klebsiella pneumoniae.
Gonzalez-Padilla M; Torre-Cisneros J; Rivera-Espinar F; Pontes-Moreno A; López-Cerero L; Pascual A; Natera C; Rodríguez M; Salcedo I; Rodríguez-López F; Rivero A; Rodríguez-Baño J
J Antimicrob Chemother; 2015 Mar; 70(3):905-13. PubMed ID: 25344809
[TBL] [Abstract][Full Text] [Related]
10. Bloodstream infections caused by metallo-β-lactamase/Klebsiella pneumoniae carbapenemase-producing K. pneumoniae among intensive care unit patients in Greece: risk factors for infection and impact of type of resistance on outcomes.
Mouloudi E; Protonotariou E; Zagorianou A; Iosifidis E; Karapanagiotou A; Giasnetsova T; Tsioka A; Roilides E; Sofianou D; Gritsi-Gerogianni N
Infect Control Hosp Epidemiol; 2010 Dec; 31(12):1250-6. PubMed ID: 20973725
[TBL] [Abstract][Full Text] [Related]
11. Successful Treatment of Carbapenemase-Producing Pandrug-Resistant Klebsiella pneumoniae Bacteremia.
Camargo JF; Simkins J; Beduschi T; Tekin A; Aragon L; Pérez-Cardona A; Prado CE; Morris MI; Abbo LM; Cantón R
Antimicrob Agents Chemother; 2015 Oct; 59(10):5903-8. PubMed ID: 26386029
[TBL] [Abstract][Full Text] [Related]
12. Doripenem MICs and ompK36 porin genotypes of sequence type 258, KPC-producing Klebsiella pneumoniae may predict responses to carbapenem-colistin combination therapy among patients with bacteremia.
Shields RK; Nguyen MH; Potoski BA; Press EG; Chen L; Kreiswirth BN; Clarke LG; Eschenauer GA; Clancy CJ
Antimicrob Agents Chemother; 2015 Mar; 59(3):1797-801. PubMed ID: 25534733
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcome of dual colistin- and carbapenem-resistant Klebsiella pneumoniae bloodstream infections: A single-center retrospective study of 75 cases in India.
Kaur A; Gandra S; Gupta P; Mehta Y; Laxminarayan R; Sengupta S
Am J Infect Control; 2017 Nov; 45(11):1289-1291. PubMed ID: 28807425
[TBL] [Abstract][Full Text] [Related]
14. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy.
Tumbarello M; Viale P; Viscoli C; Trecarichi EM; Tumietto F; Marchese A; Spanu T; Ambretti S; Ginocchio F; Cristini F; Losito AR; Tedeschi S; Cauda R; Bassetti M
Clin Infect Dis; 2012 Oct; 55(7):943-50. PubMed ID: 22752516
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic strategy for pandrug-resistant Klebsiella pneumoniae severe infections: short-course treatment with colistin increases the in vivo and in vitro activity of double carbapenem regimen.
Oliva A; Mascellino MT; Cipolla A; D'Abramo A; De Rosa A; Savinelli S; Ciardi MR; Mastroianni CM; Vullo V
Int J Infect Dis; 2015 Apr; 33():132-4. PubMed ID: 25597275
[TBL] [Abstract][Full Text] [Related]
16. Might real-time pharmacokinetic/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae?
Pea F; Della Siega P; Cojutti P; Sartor A; Crapis M; Scarparo C; Bassetti M
Int J Antimicrob Agents; 2017 Feb; 49(2):255-258. PubMed ID: 28012683
[TBL] [Abstract][Full Text] [Related]
17. Population Pharmacokinetics of High-Dose Continuous-Infusion Meropenem and Considerations for Use in the Treatment of Infections Due to KPC-Producing Klebsiella pneumoniae.
Cojutti P; Sartor A; Righi E; Scarparo C; Bassetti M; Pea F
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28760900
[TBL] [Abstract][Full Text] [Related]
18. Epidemiology of Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections in a Chinese Children's Hospital: Predominance of New Delhi Metallo-β-Lactamase-1.
Dong F; Zhang Y; Yao K; Lu J; Guo L; Lyu S; Yang Y; Wang Y; Zheng H; Song W; Liu G
Microb Drug Resist; 2018 Mar; 24(2):154-160. PubMed ID: 28594635
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for bloodstream infections due to colistin-resistant KPC-producing Klebsiella pneumoniae: results from a multicenter case-control-control study.
Giacobbe DR; Del Bono V; Trecarichi EM; De Rosa FG; Giannella M; Bassetti M; Bartoloni A; Losito AR; Corcione S; Bartoletti M; Mantengoli E; Saffioti C; Pagani N; Tedeschi S; Spanu T; Rossolini GM; Marchese A; Ambretti S; Cauda R; Viale P; Viscoli C; Tumbarello M;
Clin Microbiol Infect; 2015 Dec; 21(12):1106.e1-8. PubMed ID: 26278669
[TBL] [Abstract][Full Text] [Related]
20. Carbapenem-sparing antibiotic regimens for infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae in intensive care unit.
Sbrana F; Malacarne P; Viaggi B; Costanzo S; Leonetti P; Leonildi A; Casini B; Tascini C; Menichetti F
Clin Infect Dis; 2013 Mar; 56(5):697-700. PubMed ID: 23155147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
